Exploring the Relationship between Anti-VEGF Therapy and Glaucoma: Implications for Management Strategies.
anti-VEGF
elevated intraocular pressure
glaucoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Jul 2023
14 Jul 2023
Historique:
received:
09
04
2023
revised:
03
07
2023
accepted:
12
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
A short-term increase in intraocular pressure (IOP) is a common side effect after intravitreal anti-VEGF therapy, but a sustained increase in IOP with the development of secondary glaucoma has also been reported in some studies after repeated intravitreal anti-VEGF injections. The aim of this review is to present and discuss the possible pathophysiological mechanisms and factors contributing to a sustained rise in IOP, as well as treatment strategies for patients at risk. Close monitoring and adjustable IOP-lowering treatment are recommended for high-risk patients, including those with glaucoma, angle-closure anomalies, ocular hypertension or family history of glaucoma; patients receiving a high number of injections or at shorter intervals; and patients with capsulotomy. Strategies are needed to identify patients at risk in a timely manner and to prevent sustained elevation of IOP.
Identifiants
pubmed: 37510790
pii: jcm12144674
doi: 10.3390/jcm12144674
pmc: PMC10380425
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Glaucoma. 2022 Jun 1;31(6):361-374
pubmed: 35394454
Drugs. 2022 May;82(7):825-830
pubmed: 35474059
Clin Ophthalmol. 2019 Dec 24;13:2563-2572
pubmed: 31920279
Retina. 2015 May;35(5):841-58
pubmed: 25905784
Ophthalmic Surg Lasers Imaging Retina. 2013 Sep-Oct;44(5):460-4
pubmed: 24044708
Prog Retin Eye Res. 2003 Jan;22(1):1-29
pubmed: 12597922
J Fr Ophtalmol. 2018 Oct;41(8):e329-e340
pubmed: 30197188
Can J Ophthalmol. 2007 Dec;42(6):807-11
pubmed: 18026202
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Cochrane Database Syst Rev. 2019 Mar 04;3:CD005139
pubmed: 30834517
J Glaucoma. 2016 Mar;25(3):291-300
pubmed: 25318578
Drug Des Devel Ther. 2016 Jun 02;10:1857-67
pubmed: 27330279
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1893-1898
pubmed: 28358961
Kidney Int. 2019 Sep;96(3):572-580
pubmed: 31229276
Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):955-8
pubmed: 18425523
Eur J Ophthalmol. 2023 Apr 10;:11206721231168146
pubmed: 37038334
Sci Rep. 2020 Aug 6;10(1):13248
pubmed: 32764619
Am J Ophthalmol. 2021 Jun;226:206-216
pubmed: 33359714
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6501-5
pubmed: 26447985
J Fr Ophtalmol. 2017 Mar;40(3):e77-e82
pubmed: 28284658
Eye (Lond). 2018 Jun;32(6):1010-1020
pubmed: 29398697
Retina. 2011 Jun;31(6):1028-35
pubmed: 21836409
J Ocul Pharmacol Ther. 2015 Feb;31(1):2-10
pubmed: 25369256
Int Ophthalmol. 2015 Aug;35(4):473-80
pubmed: 25059401
Br J Ophthalmol. 2009 Apr;93(4):457-62
pubmed: 19033289
J Ophthalmic Vis Res. 2014 Oct-Dec;9(4):449-52
pubmed: 25709770
Sci Rep. 2016 Dec 21;6:39301
pubmed: 28000707
Retina. 2013 Jan;33(1):179-87
pubmed: 22990314
J Glaucoma. 2012 Apr-May;21(4):241-7
pubmed: 21423038
Invest Ophthalmol Vis Sci. 2011 Feb 22;52(2):1023-34
pubmed: 21051703
Ophthalmology. 2012 Feb;119(2):321-6
pubmed: 22054994
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9944-8
pubmed: 10449799
Clin Ophthalmol. 2014 Mar 25;8:599-604
pubmed: 24707164
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1459-1466
pubmed: 31053943
J Ocul Pharmacol Ther. 2010 Feb;26(1):105-10
pubmed: 20187807
Acta Ophthalmol. 2014 Dec;92(8):713-23
pubmed: 24925048
Ophthalmology. 2018 Apr;125(4):522-528
pubmed: 29146306
Ophthalmologica. 2013;229(3):168-72
pubmed: 23548723
Retina. 2012 Jul;32(7):1295-301
pubmed: 22466465
JAMA Ophthalmol. 2017 Apr 1;135(4):363-368
pubmed: 28301639
Ophthalmology. 2022 May;129(5):498-508
pubmed: 34871637
J Glaucoma. 2021 Dec 1;30(12):1019-1026
pubmed: 34086610
Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):293-5
pubmed: 19485295
PLoS One. 2014 Oct 17;9(10):e110397
pubmed: 25329670
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Retina. 2014 Nov;34(11):2161-6
pubmed: 25072648
Graefes Arch Clin Exp Ophthalmol. 2012 Oct;250(10):1435-40
pubmed: 22434210
Invest Ophthalmol Vis Sci. 2012 Sep 14;53(10):6214-8
pubmed: 22915037
Retina. 2020 Apr;40(4):648-656
pubmed: 30762649
Ophthalmology. 2014 May;121(5):1102-8
pubmed: 24393349
J Glaucoma. 2014 Sep;23(7):446-8
pubmed: 23632401
Retina. 2010 Jun;30(6):887-92
pubmed: 20458261
Open Ophthalmol J. 2010 Jun 22;4:28-9
pubmed: 20871754
Int J Mol Sci. 2020 Nov 03;21(21):
pubmed: 33153227
Ophthalmology. 2019 Apr;126(4):611-622
pubmed: 30472176
Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1217-1224
pubmed: 29134820
Ophthalmology. 2015 Sep;122(9):1802-10
pubmed: 26025097
Invest Ophthalmol Vis Sci. 1999 Nov;40(12):2884-91
pubmed: 10549648
J Curr Glaucoma Pract. 2013 Jan-Apr;7(1):19-24
pubmed: 26997776
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195
Retina. 2013 May;33(5):946-52
pubmed: 23407351
Eye (Lond). 2014 Oct;28(10):1218-22
pubmed: 25081290
Int J Ophthalmol. 2020 Jan 18;13(1):79-84
pubmed: 31956574
Graefes Arch Clin Exp Ophthalmol. 2019 Sep;257(9):1931-1939
pubmed: 31152311
Korean J Ophthalmol. 2016 Apr;30(2):114-20
pubmed: 27051259
Br J Ophthalmol. 2011 Aug;95(8):1111-4
pubmed: 20702430
Invest Ophthalmol Vis Sci. 2014 Aug 14;55(8):5005-15
pubmed: 25125670